ATE296821T1 - Triarylimidazol-derivate als cytokin-inhibitoren - Google Patents
Triarylimidazol-derivate als cytokin-inhibitorenInfo
- Publication number
- ATE296821T1 ATE296821T1 AT01915488T AT01915488T ATE296821T1 AT E296821 T1 ATE296821 T1 AT E296821T1 AT 01915488 T AT01915488 T AT 01915488T AT 01915488 T AT01915488 T AT 01915488T AT E296821 T1 ATE296821 T1 AT E296821T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- cytokine inhibitors
- triarylimidazole
- derivatives
- triarylimidazole derivatives
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title 1
- 108090000695 Cytokines Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0007405.4A GB0007405D0 (en) | 2000-03-27 | 2000-03-27 | Compounds |
| PCT/GB2001/001314 WO2001072737A1 (en) | 2000-03-27 | 2001-03-26 | Triarylimidazole derivatives as cytokine inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE296821T1 true ATE296821T1 (de) | 2005-06-15 |
Family
ID=9888509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01915488T ATE296821T1 (de) | 2000-03-27 | 2001-03-26 | Triarylimidazol-derivate als cytokin-inhibitoren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6906089B2 (de) |
| EP (1) | EP1268465B1 (de) |
| JP (1) | JP2003528870A (de) |
| AT (1) | ATE296821T1 (de) |
| AU (1) | AU4257901A (de) |
| CO (1) | CO5280078A1 (de) |
| DE (1) | DE60111205D1 (de) |
| GB (1) | GB0007405D0 (de) |
| WO (1) | WO2001072737A1 (de) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040039198A1 (en) * | 2000-11-16 | 2004-02-26 | Bender Paul E. | Compounds |
| US20040087623A1 (en) * | 2001-02-02 | 2004-05-06 | Gellibert Francoise Jeanne | Pyrazole derivatives against tgf overexpression |
| ES2291455T3 (es) | 2001-03-12 | 2008-03-01 | Avanir Pharmaceuticals | Compuestos de bencimidazol para modular ige e inhibir la proliferacion celular. |
| HRP20030961B1 (en) | 2001-05-24 | 2012-01-31 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
| GB0127430D0 (en) * | 2001-11-15 | 2002-01-09 | Smithkline Beecham Corp | Compounds |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| GB0217783D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| AU2003260345A1 (en) * | 2002-07-31 | 2004-02-23 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| AU2003256297A1 (en) | 2002-08-09 | 2004-02-25 | Eli Lilly And Company | Benzimidazoles and benzothiazoles as inhibitors of map kinase |
| UA80295C2 (en) | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| TWI276631B (en) | 2002-09-12 | 2007-03-21 | Avanir Pharmaceuticals | Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation |
| WO2004024655A2 (en) | 2002-09-12 | 2004-03-25 | Avanir Pharmaceuticals | Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation |
| MXPA05002332A (es) | 2002-09-18 | 2005-06-08 | Pfizer Prod Inc | Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf). |
| OA12927A (en) | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Novel triazole and oxazole compounds as transforming growth factor (TGF) inhibitors. |
| OA12925A (en) | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors. |
| KR20050057392A (ko) | 2002-09-18 | 2005-06-16 | 화이자 프로덕츠 인크. | 전환성장인자(ｔｇｆ) 억제제로서의 신규한 이미다졸 화합물 |
| OA12929A (en) | 2002-09-18 | 2006-10-13 | Pfizer Prod Inc | Pyrazole derivatives as transforming growth (TGF) inhibitors. |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| AU2003267728A1 (en) * | 2002-10-18 | 2004-05-04 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| JP2006217801A (ja) * | 2003-01-15 | 2006-08-24 | Kirin Brewery Co Ltd | ＴＧＦβ阻害活性を有する化合物の新規用途 |
| PA8595001A1 (es) | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| KR20050122210A (ko) | 2003-03-17 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
| MXJL05000041A (es) * | 2003-04-10 | 2005-12-22 | Avanir Pharmaceuticals | Compuestos de imidazol para el tratamiento de padecimientos alergicos e hiperproliferativos. |
| TWI332003B (en) * | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
| US7678810B2 (en) | 2004-03-05 | 2010-03-16 | Taisho Pharmaceutical Co., Ltd | Thiazole derivative |
| KR100749566B1 (ko) * | 2004-04-21 | 2007-08-16 | 이화여자대학교 산학협력단 | Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체 |
| US20080319012A1 (en) | 2004-04-21 | 2008-12-25 | In2Gen Co., Ltd. | 2-Pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| CA2576734C (en) * | 2004-07-29 | 2010-03-16 | Schering-Plough Ltd. | Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals |
| JP2008524246A (ja) | 2004-12-16 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| WO2006122319A2 (en) | 2005-05-11 | 2006-11-16 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| ZA200800901B (en) | 2005-07-14 | 2010-05-26 | Takeda San Diego Inc | Histone deacetylase inhibitors |
| WO2008071605A2 (en) * | 2006-12-15 | 2008-06-19 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| WO2008136739A1 (en) * | 2007-05-04 | 2008-11-13 | Jana Pickova | Compound feed for aquaculture |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| TW200911237A (en) | 2007-08-03 | 2009-03-16 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| WO2009047163A1 (en) * | 2007-10-10 | 2009-04-16 | F. Hoffmann-La Roche Ag | Methods of treating inflammatory diseases |
| JP2011513203A (ja) * | 2008-03-14 | 2011-04-28 | 大塚製薬株式会社 | Ｍｍｐ−２及び／又はｍｍｐ−９阻害剤 |
| BRPI0908906A2 (pt) * | 2008-03-21 | 2019-09-24 | Novartis Ag | compostos heterocíclicos e usos dos mesmos |
| US8865732B2 (en) | 2008-03-21 | 2014-10-21 | Novartis Ag | Heterocyclic compounds and uses thereof |
| US8513222B2 (en) | 2010-06-29 | 2013-08-20 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| USRE47141E1 (en) | 2010-06-29 | 2018-11-27 | EWHA University—Industry Collaboration Foundation | Methods of treating fibrosis, cancer and vascular injuries |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| EP2476672A1 (de) | 2010-12-22 | 2012-07-18 | Momentive Specialty Chemicals Research Belgium S.A. | Glycidylester von alpha,alpha-verzweigten Säurezusammensetzungen |
| AU2012281281B2 (en) | 2011-07-13 | 2017-06-01 | Tiumbio Co., Ltd | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors |
| DK2855665T3 (da) | 2012-05-30 | 2019-11-04 | Univ Cornell | Tilvejebringelse af funktionelle og bestandige endotele celler fra humane amnionvæske-afledte celler |
| ES2791778T3 (es) | 2012-08-01 | 2020-11-05 | Ikaika Therapeutics Llc | Mitigación del daño tisular y la fibrosis a través de anticuerpos anti-LTBP4 |
| CN105229144A (zh) | 2013-02-22 | 2016-01-06 | 细胞动力学国际有限公司 | 通过组合的遗传工程和化学工程经由正向编程产生肝细胞 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| CA2914615C (en) | 2013-06-05 | 2023-10-17 | Biotime, Inc. | Compositions and methods for induced tissue regeneration in mammalian species |
| US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
| WO2015164228A1 (en) | 2014-04-21 | 2015-10-29 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
| US10240127B2 (en) | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| CN108779435B (zh) | 2015-12-07 | 2022-05-03 | 再生疗法有限公司 | 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法 |
| EP3515446B1 (de) | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutische kombinationen mit einem raf-hemmer und einem erk-hemmer |
| US11266653B2 (en) | 2017-05-02 | 2022-03-08 | Novartis Ag | Combination therapy |
| AU2019396360A1 (en) | 2018-12-11 | 2021-05-27 | Theravance Biopharma R&D Ip, Llc | Naphthyridine and quinoline derivatives useful as ALK5 inhibitors |
| WO2020132647A1 (en) | 2018-12-21 | 2020-06-25 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
| ES3025633T3 (en) | 2019-05-13 | 2025-06-09 | Novartis Ag | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| IL293084A (en) | 2019-11-22 | 2022-07-01 | Theravance Biopharma R& D Ip Llc | Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors |
| EP4087657A1 (de) | 2020-01-08 | 2022-11-16 | Synthis Therapeutics, Inc. | Alk5-inhibitoren, konjugate und verwendungen davon |
| AU2021307560A1 (en) | 2020-07-15 | 2023-02-23 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine amino derivatives as ALK5 inhibitors |
| US20240116947A1 (en) | 2020-07-15 | 2024-04-11 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| BR112023000588A8 (pt) | 2020-07-15 | 2023-05-09 | Chiesi Farm Spa | Derivados de piridazinil amino como inibidores de alk5 |
| EP4267584A1 (de) | 2020-12-23 | 2023-11-01 | Chiesi Farmaceutici S.p.A. | Pyridooxazinderivate als alk5-inhibitoren |
| AU2022351219A1 (en) | 2021-09-21 | 2024-05-02 | Chiesi Farmaceutici S.P.A. | Pyridazinyl amino derivatives as alk5 inhibitors |
| EP4514802A1 (de) | 2022-04-27 | 2025-03-05 | Chiesi Farmaceutici S.p.A. | Imidazolderivate als alk5-inhibitoren |
| EP4727586A1 (de) | 2023-06-13 | 2026-04-22 | Synthis Therapeutics, Inc. | Anti-cd5-antikörper und ihre verwendungen |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH561202A5 (de) * | 1971-05-10 | 1975-04-30 | Ciba Geigy Ag | |
| MX9300141A (es) | 1992-01-13 | 1994-07-29 | Smithkline Beecham Corp | Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. |
| WO1998021957A1 (en) * | 1996-11-20 | 1998-05-28 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
| US5955480A (en) | 1996-11-20 | 1999-09-21 | Merck & Co., Inc. | Triaryl substituted imidazoles, compositions containing such compounds and methods of use |
| JPH11180958A (ja) * | 1997-12-24 | 1999-07-06 | Yamanouchi Pharmaceut Co Ltd | 新規アミン誘導体 |
| JP2002541253A (ja) | 1999-04-09 | 2002-12-03 | スミスクライン・ビーチャム・コーポレイション | トリアリールイミダゾール |
-
2000
- 2000-03-27 GB GBGB0007405.4A patent/GB0007405D0/en not_active Ceased
-
2001
- 2001-03-26 AU AU42579/01A patent/AU4257901A/en not_active Abandoned
- 2001-03-26 EP EP01915488A patent/EP1268465B1/de not_active Expired - Lifetime
- 2001-03-26 JP JP2001570648A patent/JP2003528870A/ja not_active Withdrawn
- 2001-03-26 DE DE60111205T patent/DE60111205D1/de not_active Expired - Lifetime
- 2001-03-26 US US10/239,815 patent/US6906089B2/en not_active Expired - Fee Related
- 2001-03-26 WO PCT/GB2001/001314 patent/WO2001072737A1/en not_active Ceased
- 2001-03-26 AT AT01915488T patent/ATE296821T1/de not_active IP Right Cessation
- 2001-03-27 CO CO01024184A patent/CO5280078A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1268465A1 (de) | 2003-01-02 |
| US6906089B2 (en) | 2005-06-14 |
| US20030149277A1 (en) | 2003-08-07 |
| CO5280078A1 (es) | 2003-05-30 |
| EP1268465B1 (de) | 2005-06-01 |
| AU4257901A (en) | 2001-10-08 |
| GB0007405D0 (en) | 2000-05-17 |
| JP2003528870A (ja) | 2003-09-30 |
| DE60111205D1 (de) | 2005-07-07 |
| WO2001072737A1 (en) | 2001-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60111205D1 (de) | Triarylimidazol-derivate als cytokin-inhibitoren | |
| ATE231143T1 (de) | Triarylimidazole | |
| MXPA02011974A (es) | Derivados de quinazolina sustituidos y su uso como inhibidores. | |
| ATE394383T1 (de) | Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren | |
| DE60322359D1 (de) | Imidazopyridinderivate als kinaseinhibitoren | |
| EP1340755A4 (de) | Mittel mit wirkung gegen helicobacter | |
| DE60112306D1 (de) | Kondensierte pyrazindionderivate als pde5 inhibitore | |
| PH12009500610A1 (en) | 4-imidazolin-2-one compounds | |
| ATE303384T1 (de) | 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren | |
| GEP20053626B (en) | Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof | |
| AU2001263278A1 (en) | Cyclic gmp-specific phosphodiesterase inhibitors | |
| DE69619259D1 (de) | Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase | |
| ATE259813T1 (de) | Triazolopyrimidinderivate | |
| DE60121048D1 (de) | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE | |
| WO2003031414A1 (en) | Novel heterocyclic compound and anti-inflammatory agent | |
| NO20022123L (no) | Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII | |
| AU2001296699A1 (en) | Condensed pyrazindione derivatives as pde inhibitors | |
| DE60122559D1 (de) | Indolderivate als pde5-inhibitoren | |
| NO20033131L (no) | Anvendelse av 2-amino-4-pyridylmetyl-tiazolinderivater som inhibitorer forinduktibel NO-syntase | |
| ATE348800T1 (de) | 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren | |
| CA2423357A1 (en) | Fused heterocyclic derivatives as phosphodiesterase inhibitors | |
| WO2002080918A1 (en) | Remedial or prophylactic agent for frequent urination or urinary incontinence | |
| ATE374751T1 (de) | 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern | |
| ATE364382T1 (de) | Hemmer der aggregation von polyq | |
| DK0651747T3 (da) | Carbostyrilderivater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |